Skip to main content
Lori Leslie, MD, Oncology, Hackensack, NJ

LoriAnnLeslieMD

Oncology Hackensack, NJ

Hematologic Oncology

Lymphoma Attending, John Theurer Cancer Center -- Director, Indolent Lymphoma and CLL research programs -- Medical Co-Directory of Oncology, Mountainside Medical Center -- Assistant Professor of Medicine, Hackensack Meridian School of Medicine

Dr. Leslie is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Leslie's full profile

Already have an account?

  • Office

    92 2nd St
    Hackensack, NJ 07601
    Phone+1 551-996-3033
    Fax+1 551-996-0573

Summary

  • As director of the Indolent Lymphoma and CLL Research Programs at John Theurer Cancer Center, I treat all types of lymphoma and work as part of a research team involved in numerous studies resulting in FDA-approved agents in B-cell disorders. These new therapies have helped launch an exciting new era in lymphoma treatment, with 60% of all lymphomas now being treatable.
  • Lori Leslie, M.D., treats all types of lymphoma

    Dr. Lori Leslie, director of the Indolent Lymphoma and CCL Research Programs at John Theurer Cancer Center, treats all types of lymphoma. Dr. Leslie has par...

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
  • New York Presbyterian Hospital (Columbia Campus)
    New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2009 - 2012
  • Columbia University Vagelos College of Physicians and Surgeons
    Columbia University Vagelos College of Physicians and SurgeonsClass of 2009

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2011 - 2026
  • NJ State Medical License
    NJ State Medical License 2015 - 2025
  • TX State Medical License
    TX State Medical License 2012 - 2015
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
    Lori A. Leslie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
    Lori A. Leslie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • CAR-T Destined for Earlier Lines of Therapy in Blood Cancers, Experts Say
    CAR-T Destined for Earlier Lines of Therapy in Blood Cancers, Experts SayNovember 18th, 2022
  • EFS Improvement with Axi-Cel CAR-T a ‘Breakthrough’ in Second-Line Treatment of DLBCL
    EFS Improvement with Axi-Cel CAR-T a ‘Breakthrough’ in Second-Line Treatment of DLBCLDecember 11th, 2021
  • Understanding Lymphoma
    Understanding LymphomaJuly 19th, 2021
  • Join now to see all

Other Languages

  • Spanish